162 related articles for article (PubMed ID: 17699848)
21. Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues.
Kim KH; Choi JS; Kim IJ; Ku JL; Park JG
World J Gastroenterol; 2006 Sep; 12(35):5651-7. PubMed ID: 17007017
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic control of MAGE gene expression by the KIT tyrosine kinase.
Yang B; Wu J; Maddodi N; Ma Y; Setaluri V; Longley BJ
J Invest Dermatol; 2007 Sep; 127(9):2123-8. PubMed ID: 17495964
[TBL] [Abstract][Full Text] [Related]
23. Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters.
Wischnewski F; Friese O; Pantel K; Schwarzenbach H
Mol Cancer Res; 2007 Jul; 5(7):749-59. PubMed ID: 17634428
[TBL] [Abstract][Full Text] [Related]
24. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis.
Cha JY; Lambert QT; Reuther GW; Der CJ
Mol Cancer Res; 2008 Mar; 6(3):435-45. PubMed ID: 18337450
[TBL] [Abstract][Full Text] [Related]
25. Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein.
Schwarzenbach H; Eichelser C; Steinbach B; Tadewaldt J; Pantel K; Lobanenkov V; Loukinov D
BMC Cancer; 2014 Nov; 14():796. PubMed ID: 25363021
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
Moreno-Bost A; Szmania S; Stone K; Garg T; Hoerring A; Szymonifka J; Shaughnessy J; Barlogie B; Prentice HG; van Rhee F
Cytotherapy; 2011 May; 13(5):618-28. PubMed ID: 21171821
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.
Schirmer U; Fiegl H; Pfeifer M; Zeimet AG; Müller-Holzner E; Bode PK; Tischler V; Altevogt P
BMC Cancer; 2013 Mar; 13():156. PubMed ID: 23530769
[TBL] [Abstract][Full Text] [Related]
28. Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants.
Lin J; Lin L; Thomas DG; Greenson JK; Giordano TJ; Robinson GS; Barve RA; Weishaar FA; Taylor JM; Orringer MB; Beer DG
Clin Cancer Res; 2004 Sep; 10(17):5708-16. PubMed ID: 15355897
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic control in pituitary tumors.
Ezzat S
Endocr J; 2008 Dec; 55(6):951-7. PubMed ID: 18628575
[TBL] [Abstract][Full Text] [Related]
30. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics.
D'Agostino M; Sponziello M; Puppin C; Celano M; Maggisano V; Baldan F; Biffoni M; Bulotta S; Durante C; Filetti S; Damante G; Russo D
J Mol Endocrinol; 2014 Apr; 52(2):121-31. PubMed ID: 24353283
[TBL] [Abstract][Full Text] [Related]
31. Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survival.
Ayyoub M; Scarlata CM; Hamaï A; Pignon P; Valmori D
J Immunother; 2014; 37(2):73-6. PubMed ID: 24509169
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b.
James SR; Link PA; Karpf AR
Oncogene; 2006 Nov; 25(52):6975-85. PubMed ID: 16715135
[TBL] [Abstract][Full Text] [Related]
33. Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE.
Tannheimer SL; Rehemtulla A; Ethier SP
Breast Cancer Res; 2000; 2(4):311-20. PubMed ID: 11056689
[TBL] [Abstract][Full Text] [Related]
34. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate.
Naimi B; Latil A; Fournier G; Mangin P; Cussenot O; Berthon P
Prostate; 2002 Aug; 52(3):245-52. PubMed ID: 12111699
[TBL] [Abstract][Full Text] [Related]
36. Expression of family A melanoma antigen in human gastric carcinoma.
Jung EJ; Kim MA; Lee HS; Yang HK; Lee YM; Lee BL; Kim WH
Anticancer Res; 2005; 25(3B):2105-11. PubMed ID: 16158951
[TBL] [Abstract][Full Text] [Related]
37. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer.
Ricol D; Cappellen D; El Marjou A; Gil-Diez-de-Medina S; Girault JM; Yoshida T; Ferry G; Tucker G; Poupon MF; Chopin D; Thiery JP; Radvanyi F
Oncogene; 1999 Dec; 18(51):7234-43. PubMed ID: 10602477
[TBL] [Abstract][Full Text] [Related]
38. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.
Bai A; Meetze K; Vo NY; Kollipara S; Mazsa EK; Winston WM; Weiler S; Poling LL; Chen T; Ismail NS; Jiang J; Lerner L; Gyuris J; Weng Z
Cancer Res; 2010 Oct; 70(19):7630-9. PubMed ID: 20709759
[TBL] [Abstract][Full Text] [Related]
39. Expression spectrum and methylation-dependent regulation of melanoma antigen-encoding gene family members in pancreatic cancer cells.
Bert T; Lubomierski N; Gangsauge S; Münch K; Printz H; Prasnikar N; Robbel C; Simon B
Pancreatology; 2002; 2(2):146-54. PubMed ID: 12123095
[TBL] [Abstract][Full Text] [Related]
40. MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors.
Grau E; Oltra S; Martínez F; Orellana C; Cañete A; Fernández JM; Hernández-Martí M; Castel V
J Cancer Res Clin Oncol; 2009 Apr; 135(4):523-31. PubMed ID: 18820946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
